Fidelity Investments’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Fidelity Investments’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,000	Closed	-$1K	–	5671
2021 Q4	$1K	Buy	+1,000	New	+$1.77K	﹤0.01%	4247
2018 Q1	–	Sell	-133,839	Closed	-$5.64M	–	2751
2017 Q4	$5.64M	Sell	133,839 -269,543	-67%	-$12.1M	﹤0.01%	2135
2017 Q3	$22.2M	Sell	403,382 -501,072	-55%	-$84.5M	﹤0.01%	1659
2017 Q2	$168M	Buy	904,454 +819,808	+969%	+$144M	0.02%	742
2017 Q1	$10.1M	Hold	84,646	–	–	﹤0.01%	1965
2016 Q4	$8.41M	Hold	84,646	–	–	﹤0.01%	2032
2016 Q3	$9.48M	Sell	84,646 -35,400	-29%	-$4.25M	﹤0.01%	2002
2016 Q2	$12.3M	Sell	120,046 -27,000	-18%	-$2.7M	﹤0.01%	1871
2016 Q1	$13.5M	Sell	147,046 -38,538	-21%	-$4.11M	﹤0.01%	1834
2015 Q4	$26.8M	Buy	185,584 +28,236	+18%	+$3.67M	﹤0.01%	1541
2015 Q3	$16.3M	Buy	+157,348	New	+$18.5M	﹤0.01%	1732

Other funds holding SIOX

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Fidelity Investments's SIOX Position: Q1 2022 in Review

Fidelity Investments sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2022, closing a stake of 1,000 shares — an estimated $1K sold.

Fidelity Investments first reported a position in SIOX in Q3 2015 and held it in 11 quarters. The position peaked at $168M in Q2 2017. 41 funds tracked by Wall St. Rank hold SIOX as of Q1 2022.

Fidelity Investments reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Fidelity Investments sold 1,000 Sio Gene Therapies Inc. Common Stock shares in Q1 2022, an estimated $1K.
Fidelity Investments first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2015 and held it in 11 quarters.
Fidelity Investments's Sio Gene Therapies Inc. Common Stock position peaked at $168M in Q2 2017.
41 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2022.

Based on Fidelity Investments's 13F filing for Q1 2022, filed 13 May 2022.